Benchmark reaffirms TAT Technologies stock rating citing supply chain delays By Investing.com

Benchmark reiterated a Buy rating on TAT Technologies and kept its $66 price target, implying 77% upside from the current $37.27 share price. The firm said supply chain constraints are delaying the company’s commercial ramp through at least the first half of 2026, but still sees strong underlying demand, a growing backlog, and an eventual sentiment reversal as conditions ease. The stock remains down 13% year-to-date despite Q4 2025 revenue rising 13% year over year to $46.5 million.

Analysis

The core setup is not a demand problem but a timing problem: backlog and price targets imply the market is discounting a temporary supply bottleneck as if it were quasi-permanent. That creates a classic mispricing window where reported growth decelerates before earnings power does, which often sets up for a violent rerating once operating leverage reappears. In aviation MRO, deferred work tends to stack rather than disappear, so a normalization in the supply chain can produce a step-function in utilization and margin expansion rather than a gradual recovery.

The second-order winner is likely not just the company, but the segment’s backlog visibility premium. If peers are facing similar parts delays, then names with cleaner working capital, less complex inventories, and better vendor diversification should outperform on any evidence of easing lead times; the market usually rewards the first company to show a gross margin inflection, not the one with the best long-term demand. Conversely, if the bottleneck persists into mid-2026, the risk is that customers re-source around the constraint and the rebound becomes shallower than bulls expect, especially if backlog starts to convert more slowly than headline growth suggests.

The contrarian point: the current weakness may already reflect most of the bad news, but not the duration of the delay. The stock can work if investors get confidence that this is a 2-3 quarter issue, not a structural capacity problem; if that confidence slips, multiple compression can continue even with positive analyst coverage. The clean catalyst path is sequential improvement in lead times, gross margin, and cash conversion ahead of the first half of 2026, with sentiment likely to turn before the numbers fully normalize.

Key Decisions for Investors

• Initiate a tactical long in TATT over the next 1-2 weeks on weakness, with a 6-9 month horizon; upside is driven by rerating on any evidence of supply-chain stabilization, while the key risk is the constraint persisting past mid-2026 and delaying margin inflection.
• Use a call spread in TATT (e.g., 6-12 month horizon) instead of common for defined risk: attractive if the market starts pricing a normalization path before reported earnings catch up, with limited downside if delays extend.
• Pair trade: long TATT / short a higher-multiple industrial with weaker backlog conversion or similar supply exposure, to isolate the normalization trade and reduce beta; this should outperform if the market rewards operating leverage restoration over raw growth.
• Add a trigger-based stop: if two consecutive quarters show no improvement in lead times or gross margin, reduce exposure by 50%—that would suggest the market is right about structural rather than temporary constraints.
• Watch for a catalyst trade around the next earnings cycle: if backlog remains firm while revenue re-accelerates, scale in aggressively because the stock could rerate 20-30% quickly on sentiment reversal alone.